During the past decade, Hepato-Gastroenterologie HK s.r.o. conducted 56 clinical trials. In the 10-year time frame, 56 clinical trials started and 35 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 26 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hepato-Gastroenterologie HK s.r.o." #1 sponsor was "Pfizer" with 11 trials, followed by "Celgene" with 8 trials sponsored, "Galapagos NV" with 7 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored and "Hoffmann-La Roche" with 6 trials sponsored. Other sponsors include 25 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hepato-Gastroenterologie HK s.r.o." #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator and "Galapagos NV" with 2 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Hepato-Gastroenterologie HK s.r.o." are "Ulcerative Colitis" (30 trials), "Crohn's Disease" (19 trials), "Crohn Disease" (12 trials), "Colitis, Ulcerative" (5 trials) and "Primary Biliary Cholangitis" (2 trials). Many other conditions were trialed in "Hepato-Gastroenterologie HK s.r.o." in a lesser frequency.

Most popular intervention types in "Hepato-Gastroenterologie HK s.r.o." are "Drug" (66 trials), "Other" (9 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Filgotinib" (6 trials), "CP-690,550" (5 trials), "Etrolizumab" (5 trials) and "Mirikizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Hepato-Gastroenterologie HK s.r.o." are 68 trials for "All" genders.

Currently, there are NaN active trials in "Hepato-Gastroenterologie HK s.r.o.". undefined are not yet recruiting, 11 are recruiting, 14 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 38 completed trials in Hepato-Gastroenterologie HK s.r.o., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hepato-Gastroenterologie HK s.r.o., 0 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".